4d-150
Nucleic acidexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Dec 9, 2021 (NCT05197270)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor CINHIBITOR
VEGFC inhibitor
- Vascular endothelial growth factor BINHIBITOR
VEGFB inhibitor
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07064759 | Phase 3 | Jul 22, 2025 | 4D Molecular Therapeutics |
| NCT06864988 | Phase 3 | Mar 3, 2025 | 4D Molecular Therapeutics |
| NCT05930561 | Phase 2 | Aug 9, 2023 | 4D Molecular Therapeutics |
| NCT05197270 | Phase 1/Phase 2 (Phase 2) | Dec 9, 2021 | 4D Molecular Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics | For profit | 4 | 4 | 2 | 2021 |
1 organizations
Page 1 / 1